These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8436440)

  • 1. Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines.
    McLaughlin K; Coren G; Masters J; Brown R
    Int J Cancer; 1993 Feb; 53(4):662-6. PubMed ID: 8436440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-DNA damage recognition proteins in human tumour extracts.
    Bissett D; McLaughlin K; Kelland LR; Brown R
    Br J Cancer; 1993 Apr; 67(4):742-8. PubMed ID: 8471431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteins binding to cisplatin-damaged DNA in human cell lines.
    Billings PC; Engelsberg BN; Hughes EN
    Cancer Invest; 1994; 12(6):597-604. PubMed ID: 7994594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin.
    Chao JC; Wan XS; Engelsberg BN; Rothblum LI; Billings PC
    Biochim Biophys Acta; 1996 Jun; 1307(2):213-9. PubMed ID: 8679707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA.
    Lawrence DL; Engelsberg BN; Farid RS; Hughes EN; Billings PC
    J Biol Chem; 1993 Nov; 268(32):23940-5. PubMed ID: 8226934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of host cell reactivation of cisplatin-treated adenovirus 5 in human cell lines to detect repair of drug-treated DNA.
    Maynard KR; Hosking LK; Hill BT
    Chem Biol Interact; 1989; 71(4):353-65. PubMed ID: 2582540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of high mobility group protein binding to cisplatin-damaged DNA.
    Billings PC; Davis RJ; Engelsberg BN; Skov KA; Hughes EN
    Biochem Biophys Res Commun; 1992 Nov; 188(3):1286-94. PubMed ID: 1445361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells.
    Arioka H; Nishio K; Ishida T; Fukumoto H; Fukuoka K; Nomoto T; Kurokawa H; Yokote H; Abe S; Saijo N
    Jpn J Cancer Res; 1999 Jan; 90(1):108-15. PubMed ID: 10076573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.
    Taverna P; Hansson J; Scanlon KJ; Hill BT
    Carcinogenesis; 1994 Sep; 15(9):2053-6. PubMed ID: 7923602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA repair capacity and cisplatin sensitivity of human testis tumour cells.
    Köberle B; Grimaldi KA; Sunters A; Hartley JA; Kelland LR; Masters JR
    Int J Cancer; 1997 Mar; 70(5):551-5. PubMed ID: 9052754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of human single-stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II).
    Clugston CK; McLaughlin K; Kenny MK; Brown R
    Cancer Res; 1992 Nov; 52(22):6375-9. PubMed ID: 1423284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential binding of HMG1, HMG2, and a single HMG box to cisplatin-damaged DNA.
    Farid RS; Bianchi ME; Falciola L; Engelsberg BN; Billings PC
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):532-9. PubMed ID: 8975778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iododeoxyuridine chemosensitization of cis-diamminedichloroplatinum(II) in human bladder cancer cells.
    Chi KH; Kunugi KA; Kinsella TJ
    Cancer Res; 1994 May; 54(10):2701-6. PubMed ID: 8168100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
    Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
    Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P
    Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognition of DNA interstrand cross-links of cis-diamminedichloroplatinum(II) and its trans isomer by DNA-binding proteins.
    Kaspárková J; Brabec V
    Biochemistry; 1995 Sep; 34(38):12379-87. PubMed ID: 7547982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro.
    Dempke WC; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Hill BT
    Carcinogenesis; 1992 Jul; 13(7):1209-15. PubMed ID: 1638688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms.
    Marples B; Adomat H; Billings PC; Farrell NP; Koch CJ; Skov KA
    Anticancer Drug Des; 1994 Oct; 9(5):389-99. PubMed ID: 7945723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.
    Kuppen PJ; Schuitemaker H; van 't Veer LJ; de Bruijn EA; van Oosterom AT; Schrier PI
    Cancer Res; 1988 Jun; 48(12):3355-9. PubMed ID: 2897238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of HMG protein binding to DNA modified with the anticancer drug cisplatin.
    Cryer JE; Johnson SW; Engelsberg BN; Billings PC
    Cancer Chemother Pharmacol; 1996; 38(2):163-8. PubMed ID: 8616907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.